Full Name
Chng, W.J.
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Chng, Wee Joo
Chng, W.-J.
 
Main Affiliation
 
 
Email
csicwj@nus.edu.sg
 
Other emails
 

Publications

Results 1-20 of 92 (Search time: 0.014 seconds).

Issue DateTitleAuthor(s)
12018A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphataseZhou, J ; Toh, S.H.-M; Chan, Z.-L; Quah, J.Y; Chooi, J.-Y ; Tan, T.Z ; Chong, P.S.Y ; Zeng, Q ; Chng, W.-J 
220-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
32016Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomasHirpara, J.L ; Loh, T ; Ng, S.B ; Chng, W.J ; Pervaiz, S 
42015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
528-Apr-2014Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study GroupTse, E.; Chan, T.S.Y.; Koh, L.-P.; Chng, W.-J. ; Kim, W.-S.; Tang, T.; Lim, S.-T.; Lie, A.K.W.; Kwong, Y.-L.
627-Jan-2020Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomade Mel, S.; Rashid, M.B.M.; Zhang, X.Y.; Goh, J.; Lee, C.T.; Poon, L.M.; Chan, E.H.L. ; Liu, X.; Chng, W.J. ; Chee, Y.L.; Lee, J.; Yuen, Y.C.; Lim, J.Q. ; Chia, B.K.H.; Laurensia, Y.; Huang, D.C.; Pang, W.L.; Cheah, D.M.Z.; Wong, E.K.Y.; Ong, C.K. ; Tang, T. ; Lim, S.T. ; Ng, S.B. ; Tan, S.Y. ; Loi, H.-Y. ; Tan, L.K. ; Chow, E.K. ; Jeyasekharan, A.D. 
72020ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemiaZhou, J.; Quah, J.Y. ; Ng, Y. ; Chooi, J.-Y. ; Toh, S.H.-M. ; Lin, B.; Tan, T.Z. ; Hosoi, H. ; Osato, M. ; Seet, Q.; Lisa Ooi, A.G.; Lindmark, B.; McHale, M.; Chng, W.-J. 
828-Mar-2013ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.Croxford, J.L. ; Tang, M.L.; Pan, M.F. ; Huang, C.W.; Kamran, N.; Phua, C.M.; Chng, W.J. ; Ng, S.B. ; Raulet, D.H.; Gasser, S. 
9Jul-2017Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaKong, L.R ; Tan, T.Z ; Ong, W.R; Bi, C; Huynh, H ; Lee, S.C ; Chng, W.J ; Eichhorn, P.J.A ; Goh, B.C 
1011-Jul-2018BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemiaZhou Y.; Zhou J. ; Lu X.; Tan T.-Z. ; Chng W.-J. 
1117-Mar-2017Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age SubgroupHeinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng ; Hartmut Goldschmidt; Roman Hajek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosinol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua
1222-Sep-2017Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR StudyHartmut Goldschmidt; Philippe Moreau; Heinz Ludwig; Ruben Niesvizky; Wee Joo Chng ; Douglas Joshua; Katja Weisel; Andrew Spencer; Robert Orlowski; Shibao Feng; Karim Iskander; Meletios A. Dimopoulos
132018Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myelomaShanmugam, M.K ; Ahn, K.S; Lee, J.H; Kannaiyan, R; Mustafa, N ; Manu, K.A ; Siveen, K.S ; Sethi, G ; Chng, W.J ; Kumar, A.P 
14Oct-2009Centrosomes and myeloma; aneuploidy and proliferationChng, W.J. ; Fonseca, R.
152008Clinical and biological significance of RAS mutations in multiple myelomaChng, W.J. ; Van, Wier S.; Fonseca, R.; Gonzalez-Paz, N.; Price-Troska, T.; Rajkumar, S.V.; Kyle, R.A.; Henderson, K.J.; Greipp, P.; Jacobus, S.; Oken, M.M.; Van, Ness B.
162014Clinical profiles of multiple myeloma in asia-an asian myeloma network studyKim, K.; Lee, J.H.; Kim, J.S.; Min, C.K.; Yoon, S.S.; Shimizu, K.; Chou, T.; Kosugi, H.; Suzuki, K.; Chen, W.; Hou, J.; Lu, J.; Huang, X.-J.; Huang, S.-Y.; Chng, W.J. ; Tan, D.; Teoh, G.; Chim, C.S.; Nawarawong, W.; Siritanaratkul, N.; Durie, B.G.
171-Nov-2019Comprehensive Analysis of ERK1/2 Substrates for Potential Combination ImmunotherapiesYang, Lei ; Zheng, Liangzhen; Chng, Wee Joo ; Ding, Jeak Ling 
182010Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myelomaChng, W.J. ; Van, Wier S.; Keats, J.J.; Bergsagel, P.L.; Fonseca, R.; Gertz, M.A.; Chung, T.-H. ; Baker, A.; Carpten, J.
192020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaDimopoulos, M.A.; Jakubowiak, A.J.; McCarthy, P.L.; Orlowski, R.Z.; Attal, M.; Bladé, J.; Goldschmidt, H.; Weisel, K.C.; Ramasamy, K.; Zweegman, S.; Spencer, A.; Huang, J.S.Y.; Lu, J.; Sunami, K.; Iida, S.; Chng, W.-J. ; Holstein, S.A.; Rocci, A.; Skacel, T.; Labotka, R.; Palumbo, A.; Anderson, K.C.
20Apr-2012Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivoChan, D.; Tyner, J.W.; Chng, W.J. ; Bi, C.; Okamoto, R.; Said, J.; Ngan, B.D.; Braunstein, G.D.; Koeffler, H.P.